aTyr Pharma (NASDAQ:ATYR) Downgraded by Wall Street Zen to "Sell"

Key Points

• aTyr Pharma has been downgraded by Wall Street Zen from a "hold" to a "sell" rating.
• A variety of analysts have mixed opinions on the stock, with Wells Fargo raising its target price to $25.00 while HC Wainwright set a target price of $35.00 and rated it as "buy."
• The company's recent earnings report showed a loss of ($0.22) earnings per share, which was below analysts' expectations of ($0.18).

aTyr Pharma (NASDAQ:ATYR - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

A number of other equities research analysts have also weighed in on ATYR. HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of aTyr Pharma in a report on Wednesday, June 4th. Wells Fargo & Company raised their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, June 20th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $20.20.

aTyr Pharma Price Performance

ATYR stock traded up $0.31 during trading on Friday, hitting $5.61. 4,683,222 shares of the company's stock traded hands, compared to its average volume of 2,396,001. The business has a fifty day simple moving average of $5.36 and a 200 day simple moving average of $4.14. The stock has a market capitalization of $499.31 million, a price-to-earnings ratio of -7.01 and a beta of 0.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. aTyr Pharma has a 52 week low of $1.67 and a 52 week high of $7.29.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). As a group, research analysts expect that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in shares of aTyr Pharma in the 4th quarter worth approximately $39,000. American Century Companies Inc. purchased a new position in shares of aTyr Pharma in the 4th quarter worth approximately $319,000. JPMorgan Chase & Co. grew its position in shares of aTyr Pharma by 467.8% in the 4th quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock worth $646,000 after buying an additional 147,092 shares during the last quarter. Geode Capital Management LLC purchased a new position in shares of aTyr Pharma in the 4th quarter worth approximately $3,229,000. Finally, ExodusPoint Capital Management LP purchased a new position in shares of aTyr Pharma in the 4th quarter worth approximately $61,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.